Venetoclax is a very effective treatment for chronic lymphocytic leukemia (CLL) in patients with no prior exposure to BTK inhibitors (BTKi). Still, it is less effective for patients whose disease has progressed on prior BTKi therapy.
Venetoclax is a BCL2 inhibitor that has been shown to be a very effective treatment for CLL / SLL in clinical trials both as a first-line treatment and for relapsed / refractory disease. However, in the real world, patient outcomes can differ from those seen in clinical trials partially due to the eligibility criteria used to select patients for clinical trials. This study looked at outcomes for CLL patients treated with venetoclax in routine clinical practice.
Dr. Paul Hampel from Mayo Clinic discusses the results of this study that were presented at the American Society of Hematology (ASH) Annual Meeting in December 2023.
Read the full article on CLL Society's website at: cllsociety.org...
__________________________________________________________________________________________
CLL Society Website: cllsociety.org/
Facebook: / cllsociety
Twitter: / cllsociety
LinkedIn: / cll-society